

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 July 2025 (10.07.2025)



(10) International Publication Number
WO 2025/147603 A1

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/4365 (2006.01)
A61K 31/13 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2025/010226

(22) International Filing Date:

03 January 2025 (03.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/618,195 05 January 2024 (05.01.2024) US

(71) Applicant: **DEWPOINT THERAPEUTICS, INC.**
[US/US]; 451 D Street, Suite 104, Boston, Massachusetts
02210 (US).

(72) Inventors: **RIGUET, Eric**; c/o Dewpoint Therapeutics
GmbH, Tatzberg 47, 01307 Dresden (DE). **WAGNER,
Michael**; c/o Dewpoint Therapeutics GmbH, Tatzberg 47,
01307 Dresden (DE). **MARTINEZ, Eduardo J.**; c/o Dew-
point Therapeutics, Inc., 451 D Street, Suite 104, Boston,
Massachusetts 02210 (US). **TORRES GOMEZ, Hector
Manuel**; c/o Dewpoint Therapeutics GmbH, Tatzberg 47,
01307 Dresden (DE). **LAI, Jesse Derek**; c/o Dewpoint
Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massa-
chusetts 02210 (US). **YU, Violeta**; c/o Dewpoint Therapeu-
tics, Inc., 451 D Street, Suite 104, Boston, Massachusetts
02210 (US).

(74) Agent: **JADRICH, Caleb N.** et al.; Morrison & Foerster
LLP, 755 Page Mill Road, Palo Alto, California 94304-1018
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,


NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: THIENOPYRIDINE COMPOUNDS AND USES THEREOF



(57) Abstract: Provided herein are compounds of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate of any of the foregoing, wherein R¹, R², Ring A, L, R⁶, R⁷, and R⁸ are as defined elsewhere herein. Also provided are methods of preparing compounds of formula (I). Also provided herein are methods of modulating TDP-43 and methods of treating a disease or condition mediated by TDP-43 in an individual in need thereof.



WO 2025/147603 A1